Martin O. A.
- Country
- Spain
- Department
- Medical oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 19 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator focuses on innovative strategies for HR+/HER2‑negative early breast cancer and HER2‑positive metastatic disease, integrating targeted agents with endocrine or antibody‑based regimens.
- Adjuvant endocrine therapy combined with CDK4/6 inhibition
- Antibody‑drug conjugates as induction therapy
- Minimal residual disease monitoring via circulating tumor DNA
Research aims to improve disease‑free survival and personalize treatment sequencing.
Hematologic & Myeloproliferative Disorders
Clinical work addresses disorders such as chronic phase chronic myeloid leukemia and polycythemia vera, exploring disease‑modifying agents and response metrics.
- Tyrosine kinase inhibition in BCR‑ABL1‑mutated disease
- Hematocrit control without phlebotomy
- Major molecular response as a therapeutic endpoint
Efforts target durable remission and reduced treatment burden.
Thoracic and Head & Neck Oncology
Investigations include ROS1‑positive non‑small cell lung cancer with brain metastasis and HPV‑negative head and neck squamous cell carcinoma, emphasizing targeted and combination approaches.
- Tyrosine kinase inhibitors crossing the blood‑brain barrier
- Dual EGFR and MET pathway blockade
- Intracranial objective response assessment
The goal is to extend survival and control central nervous system disease.
Cancer‑Associated Thromboembolism and Hemostasis
Research addresses management of venous thromboembolism in gastrointestinal/genitourinary cancer patients and reversal of anticoagulation during urgent procedures.
- Non‑inferiority of novel factor Xa inhibitors versus standard anticoagulants
- Andexanet alfa for rapid hemostasis
- Bleeding risk mitigation in surgical settings
Focus is on balancing thrombotic protection with procedural safety.
Autoimmune Renal Disease and Chronic Pain Management
The investigator explores therapies for primary membranous nephropathy and for patients with chronic non‑specific low back pain unresponsive to conventional analgesics.
- B‑cell directed immunomodulation
- Targeted pain‑reduction pathways
- Quality‑of‑life outcome integration
These studies aim to reduce proteinuria and improve functional capacity.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.